 |
|
Ovarian Cancer - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
1. Testing a New Drug in Advanced BRCA-related Cancer
(Posted: 09/08/2009) - In this clinical trial, women with advanced breast or ovarian cancer who carry a known BRCA gene mutation or who have a strong family history of these diseases (and are, therefore, likely to carry such a mutation) will be treated with a new drug called AZD2281 (olaparib) together with the chemotherapy drug carboplatin.
2. Targeted Treatment for Advanced Solid Tumors
(Posted: 12/16/2008) - This clinical trial combines the drug dasatinib with the angiogenesis inhibitor bevacizumab for patients with metastatic or unresectable solid tumors.
3. Defining Therapy for Recurrent Platinum-sensitive Ovarian Cancer
(Posted: 06/10/2008) - In this phase III clinical trial, women with platinum-sensitive, recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer will be randomly assigned to undergo secondary cytoreductive surgery, if they are candidates for such surgery, and then randomly assigned to chemotherapy with or without bevacizumab. Women who aren't surgical candidates will be randomized to chemotherapy with or without bevacizumab.
4. New Drug Combination for Ovarian and Primary Peritoneal Cancers
(Posted: 12/04/2007) - Women with ovarian epithelial or primary peritoneal cancer whose disease has relapsed less than 6 months after treatment with initial chemotherapy will receive cisplatin and a second drug called flavopiridol in this phase II clinical trial.
5. Zoledronate to Preserve Bone Mineral Density
(Posted: 02/27/2007) - Women undergoing risk-reducing surgical removal of their ovaries will have their bone mineral density checked prior to surgery and will receive calcium and vitamin D supplements for 18 months following surgery. Half of the women will be randomly assigned to receive intravenous zoledronate once every 6 months, while the rest will be monitored without receiving additional treatment.
1 2 3 Next >
|
|
|
